The advent of oligonucleotide therapeutics has given rise to novel drug development strategies. Oligonucleotide ligands can operate as both independent therapeutic modalities and as delivery vehicles for diverse payloads…
Optimer binders are oligonucleotide-based affinity ligands that are being employed to offer new bioprocessing solutions. Isolated from large degenerate libraries, they can bind to a range of protein and…
As part of the COVID-19 pandemic Optimer reagents were developed to the SARS-CoV-2 viral S protein. Ongoing mutations seen in SARS-CoV-2 have resulted in the emergence of variant strains…
Presented at SLAS 2021 by collaborators at Boston University showing Aptamer Group’s COVID-19 Optimers used in the high content imager platform, MuviCyte, to help further our understanding of viruses…
The reliable detection of small molecules remains a significant challenge for both diagnostic monitoring and the detection of food and environmental contaminants. Typical small molecule analysis methods…
